Optimal morphologic response to preoperative chemotherapy: An alternate outcome end point before resection of hepatic colorectal metastases

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4566-4572

  Shindoh, Junichi ^a   Loyer, Evelyne M ^a   Kopetz, Scott ^a   Boonsirikamchai, Piyaporn ^a   Maru, Dipen M ^a   Chun, Yun Shin ^b   Zimmitti, Giuseppe ^a   Curley, Steven A ^a   Charnsangavej, Chusilp ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871802981     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.2854     Document Type: Article

References (31)

1. Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818-825, 2004
2. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766, 2002
3. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722, 2005
4. Kopetz S, Vauthey JN: Perioperative chemotherapy for resectable hepatic metastases. Lancet 371:963-965, 2008
5. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004
6. Parikh AA, Gentner B, Wu TT, et al: Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7:1082-1088, 2003
7. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061, 2004
8. Allen PJ, Kemeny N, Jarnagin W, et al: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:109-115, 2003
9. Grothey A, Hedrick EE, Mass RD, et al: Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183-189, 2008
10. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
11. Sathornsumetee S, Cao Y, Marcello JE, et al: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278, 2008
12. Chun YS, Vauthey JN, Boonsirikamchai P, et al: Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338-2344, 2009
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Dindo D, Demartines N, Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-213, 2004
15. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999
16. Iwatsuki S, Dvorchik I, Madariaga JR, et al: Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system. J Am Coll Surg 189:291-299, 1999
17. Malik HZ, Prasad KR, Halazun KJ, et al: Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 246:806-814, 2007
18. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients - Association Francaise de Chirurgie. Cancer 77:1254-1262, 1996
19. Rees M, Tekkis PP, Welsh FK, et al: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg 247:125-135, 2008
20. Zakaria S, Donohue JH, Que FG, et al: Hepatic resection for colorectal metastases: Value for risk scoring systems? Ann Surg 246:183-191, 2007
21. Ayez N, Lalmahomed ZS, van der Pool AE, et al: Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol 18:2757-2763, 2011
22. Jarnagin WR: Clinical scoring systems for stratifying risk after resection of hepatic colorectal metastases: Still relevant? Ann Surg Oncol 18:2711-2713, 2011
23. Adam R, Wicherts DA, de Haas RJ, et al: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 26:1635-1641, 2008
24. Blazer DG 3rd, Kishi Y, Maru DM, et al: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344-5351, 2008
25. Rubbia-Brandt L, Giostra E, Brezault C, et al: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304, 2007
26. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008
27. Suzuki C, Blomqvist L, Sundin A, et al: The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 23:948-954, 2012
28. Vauthey JN, Rousseau DL Jr: Liver imaging: A surgeon's perspective. Clin Liver Dis 6:271-295, 2002
29. Vauthey JN: Liver imaging: A surgeon's perspective. Radiol Clin North Am 36:445-457, 1998
30. Vauthey JN, Nordlinger B, Kopetz S, et al: Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: A debate over goals of research and an approach while the jury remains out. Ann Surg Oncol 17:1983-1986, 2010
31. Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11:38-47, 2010